Mwandishi:
Mhariri:
Imeboreshwa:
ULY CLINIC
ULY CLINIC
20 Februari 2026, 04:36:31
Management based on disease severity COVID-19
There is no single curative (“magic-bullet”) therapy for COVID-19. The disease is a multi-phase viral-inflammatory syndrome, therefore treatment requires:
Stage-specific therapy
Organ support
Thrombosis prevention
Careful monitoring for deterioration
Management differs according to severity:
Mild disease (Home care)
Moderate disease (Pneumonia)
Severe disease (Severe pneumonia)
Critical disease
A. MILD COVID-19 DISEASE (HOME CARE)
Clinical Definition
Symptomatic patient without hypoxia or pneumonia
Goals of Care
Prevent progression
Reduce transmission
Provide symptom relief
Educate patient on danger signs
Discharge & Isolation Instructions
Patient must:
Self-isolate
Wear mask around others
Use separate utensils and sleeping area
Maintain hydration and nutrition
Monitor symptoms daily
Pharmacologic Treatment
Supportive Supplements
Medication | Dose | Duration | Purpose |
Vitamin C | 500 mg OD | 2 weeks | Immune modulation |
Zinc sulphate | 40 mg OD | 2 weeks | Antiviral support |
Vitamin D3 | 1000–5000 IU OD | 2 weeks | Immune regulation |
Symptomatic Treatment
Antipyretics (Paracetamol)
Antihistamine (if URTI symptoms)
Cough syrup if needed
Conditional Treatments
Only if clinically suspected:
Condition | Treatment |
Bacterial infection | Antibiotics per guideline |
Malaria positive | Antimalarial regimen |
Other infections | Treat accordingly |
Antibiotics are NOT routinely indicated
Patient Education — Danger Signs
Return immediately if:
Difficulty breathing
Chest tightness
Persistent fever
Confusion
Reduced consciousness
Remarks
Early supplements may support immune response
Community awareness reduces transmission
Zinc deficiency associated with increased infection risk
B. MODERATE COVID-19 DISEASE (PNEUMONIA)
Clinical Definition
Pneumonia with SpO₂ ≥ 90% on room air
Goals of Care
Prevent deterioration to severe disease
Reduce inflammation
Treat bacterial superinfection
Treatment Protocol
Supportive Care
Same supplements as mild disease.
Anti-Inflammatory Therapy
Drug | Dose | Duration |
Dexamethasone | 6 mg PO OD | 5 days |
OR | ||
Prednisolone | 20 mg PO OD | 5 days |
Antibiotics (If Suspected Superinfection)
Option 1
Azithromycin 500 mg OD × 5 daysPLUS
Amoxicillin/Clavulanate 625 mg BD × 7 days
Option 2
Azithromycin 500 mg OD × 5 daysPLUS
Amoxicillin 500 mg TDS × 7 days
Option 3
Azithromycin 500 mg OD × 5 daysPLUS
Ceftriaxone 1 g OD × 5 days
Monitoring
Daily symptom review
Oxygen saturation monitoring
Educate on danger signs
C. SEVERE COVID-19 DISEASE (SEVERE PNEUMONIA)
Clinical Definition
Pneumonia with hypoxia → risk ofAcute Respiratory Distress Syndrome
Admission Required
Place in oxygen-equipped isolation room
1. Oxygenation Strategy
Method | Flow Rate |
Nasal cannula | 1–5 L/min |
Face mask | 6–10 L/min |
Non-rebreather | 10–15 L/min |
CPAP/NIV | If oxygen inadequate |
Encourage awake prone positioning
2. Corticosteroids
Drug | Regimen |
Methylprednisolone | 80 mg stat → 40 mg BD × 7 days |
Hydrocortisone | 200 mg BD × 7 days |
Dexamethasone | 8 mg TDS × 7 days |
3. Anticoagulation
COVID-19 causes micro-thrombosis and may progress toSepsis
Preferred
Enoxaparin 1 mg/kg SC BD
Alternatives
Rivaroxaban 10 mg OD
Aspirin 75 mg OD
Clopidogrel 75 mg OD
4. Antibiotics
Azithromycin OR ClarithromycinPLUS
Piperacillin-tazobactam OR Ceftriaxone-Sulbactam
(Change based on culture results)
5. Additional Supportive Care
Careful IV fluids
Proton pump inhibitor
Nutrition therapy
Chest physiotherapy
Psychosocial support
6. Adjunct Therapies
Therapy | Note |
Magnesium | Prevent cytokine storm/QTc prolongation |
Ivermectin | Not recommended by major guidelines |
Vitamins | Continue supplementation |
Key Clinical Principle
Main treatment is correction of hypoxia and organ support
D. CRITICAL COVID-19 DISEASE
Includes:
Respiratory failure
Septic shock
Multi-organ dysfunction
May progress toSeptic shock
ICU ADMISSION REQUIRED
i. Airway & Ventilation
Intubate if airway not protected
Mechanical ventilation:
SpO₂ target > 90%
Tidal volume 4–8 mL/kg
Plateau pressure < 30 cmH₂O
ii. Oxygenation
High-flow oxygen → NIV → Mechanical ventilation
Awake or ventilated proning
iii. Steroids
Same as severe disease
iv. Anticoagulation
Same protocol as severe disease
v. Hemodynamic Support
IV fluids for shock
Maintain MAP ≥ 65 mmHg
Vasopressors if needed
vi. Antibiotics
Broad spectrum therapy then culture-guided
vii. Organ Support
Renal support (dialysis if needed)
Nutrition therapy
Stress ulcer prophylaxis
Physiotherapy
Investigational/Adjunct Therapies
Used in some settings:
Remdesivir
Tocilizumab
Colchicine
(Used selectively depending on protocol and availability)
CORE PRINCIPLE OF COVID-19 MANAGEMENT
Mild → symptomatic careModerate → anti-inflammatory therapySevere → oxygen + steroids + anticoagulationCritical → organ support + ICU care
References
Ministry of Health, Community Development, Gender, Elderly and Children (United Republic of Tanzania). Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. March 2021.
World Health Organization. Clinical management of severe acute respiratory infection when COVID-19 is suspected. WHO; 2020.
World Health Organization. Infection prevention and control during health care when coronavirus disease (COVID-19) is suspected or confirmed. WHO Interim Guidance; 2020.
World Health Organization. Coronavirus disease (COVID-19) Situation Report – 46. WHO; 2020.
Del Rio C, Malani PN. 2019 Novel Coronavirus—Important Information for Clinicians. JAMA. 2020;323(11):1039-1040.
Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382:1708-1720.
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of COVID-19 pneumonia in Wuhan, China. Lancet. 2020;395(10223):507-513.
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China. Lancet. 2020;395:1054-1062.
Zhao D, Yao F, Wang L, Zheng L, Gao Y, Ye J, et al. A comparative study on the clinical features of COVID-19 pneumonia to other pneumonias. Clin Infect Dis. 2020.
Yoon SH, Lee KH, Kim JY, Lee YK, Ko H, Kim KH, et al. Chest Radiographic and CT Findings of COVID-19: Analysis of Nine Patients Treated in Korea. Korean J Radiol. 2020;21(4):494-500.
Peng QY, Wang XT, Zhang LN. Findings of lung ultrasonography of COVID-19 pneumonia. Intensive Care Med. 2020.
van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN, et al. Aerosol and Surface Stability of SARS-CoV-2 compared with SARS-CoV-1. N Engl J Med. 2020;382:1564-1567.
Alhazzani W, Møller MH, Arabi YM, Loeb M, Gong MN, Fan E, et al. Surviving Sepsis Campaign Guidelines on the Management of Critically Ill Adults with COVID-19. Crit Care Med. 2020.
Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801-810.
Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, et al. Acute Respiratory Distress Syndrome: The Berlin Definition. JAMA. 2012;307(23):2526-2533.
Australian and New Zealand Intensive Care Society (ANZICS). COVID-19 Guidelines. Melbourne; 2020.
World Confederation for Physical Therapy. Physiotherapy management for COVID-19 (Version 1.0). 2020.
Queensland Health Clinical Excellence Division. COVID-19 Action Plan: Statewide General Medicine Clinical Network. 2020.
Imeandikwa:
24 Machi 2021, 14:49:23
